List of Rytary drug patents

Rytary is owned by Impax Labs Inc.

Rytary contains Carbidopa; Levodopa.

Rytary has a total of 9 drug patents out of which 1 drug patent has expired.

Expired drug patents of Rytary are:

  • US7094427

Rytary was authorised for market use on 07 January, 2015.

Rytary is available in capsule, extended release;oral dosage forms.

Rytary can be used as treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; treatment of post-encephalitic parkinsonism; treatment of post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; treatment of parkinson's disease; treatment of parkinsonism that may follow carbon monoxide intoxication or manganese intoxication, treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; method of providing a therapeutically effective and stable median blood plasma level of levodopa, treatment of parkinson's disease; treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication, treatment of parkinson's disease, treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

The generics of Rytary are possible to be released after 26 December, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7094427 IMPAX LABS INC Combination immediate release controlled release levodopa/carbidopa dosage forms
May, 2022

(8 months ago)

US8377474 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(5 years from now)

US8454998 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(5 years from now)

US8557283 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(5 years from now)

US9901640 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(5 years from now)

US9533046 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(5 years from now)

US9463246 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(5 years from now)

US9089607 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(5 years from now)

US9089608 IMPAX LABS INC Controlled release formulations of levodopa and uses thereof
Dec, 2028

(5 years from now)

Drugs and Companies using CARBIDOPA; LEVODOPA ingredient

Market Authorisation Date: 07 January, 2015

Treatment: Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease; Treatment of post-encephalitic parkinsonism; Treatment of post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Method of providing a therapeutically effective and stable median blood plasma level of levodopa

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of RYTARY before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic